Radiation dose to patients from radiopharmaceuticals: (Addendum 2 to ICRP Publication 53) ICRP Publication 80 Approved by the Commission in September 1997

Abstract

A joint Task Group of ICRP Committees 2 (Doses from Radiation Exposures) and 3 (Protection in Medicine; lead Committee for this report) has prepared a compilation of data on radiation dose to patients from radiopharmaceuticals. The report provides biokinetic models, absorbed doses, and effective doses, using ICRP Publication 60 dosimetry, for 10 new radiopharmaceuticals: [Methyl-11C]thymidine; [2-11C]thymidine; 14C urea (incl. carbon dioxide and bicarbonate); 15O water; 99mTc HIG, Pertechnegas, Technegas, and tetrofosmin; and 111In HIG and octreotide. It also provides recalculated dose data for the 19 most frequently used radiopharmaceuticals from ICRP Publication 53, using ICRP Publication 60 dosimetry, viz. 18F FDG; 51Cr EDTA; 67Ga citrate; 75Se SeHCAT; 99mTc DMSA, DTPA, RBC, IDA, large colloids, WBC, MAA, non-absorbable markers, pertechnetate, and phosphates and phosphonates; 123I Hippuran and MIBG; 131I Hippuran and NP59; and 201Tl thallous ion. Printing errors detected in ICRP Publication 53 are also listed. Furthermore, the report reproduces with minor corrections and updates, and therefore supersedes, the information on 6 radiopharmaceuticals given in Addendum 1 to ICRP Publication 53: 3H neutral fat and fatty acids; 14C neutral fat and fatty acids; 68Ga EDTA; and 99mTc HM-PAO, MAG3, and MIBI. There is an integrated index to all radiopharmaceuticals treated in ICRP publications so far, including a listing of effective doses per unit activity administered to adults. This issue of the Annals of the ICRP also includes an Addendum to ICRP Publication 72 concerning age-dependent doses to members of the public from intakes of radionuclides.